Proactive Hemodynamic Management During Cytoreductive Surgery and HIPEC
Recruiting
N/A
Interventional Study
Ovarian Cancer
Hemodynamic Instability
Fluid Overload
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 52 (estimated)
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a complex surgical procedure carried out through laparotomic approach. After CRS-HIPEC morbidity and mortality rates go up to 20%-40% and 3% respectively, and acute kidney injury and pulmonary effusion/oedema are the most frequent postoperative complications.
Intraoperative hypotension and risk of fluid overload…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* age \> 18 years
* patient scheduled for CRS for ovarian cancer
Exclusion Criteria:
* patients' refusal
* cardiac arrythmia
* pregnancy.
Contacts